Fig. 6
From: Synthesis of a gadolinium based-macrocyclic MRI contrast agent for effective cancer diagnosis
a Time-course in vivo T1-weighted MR images of HCT 116 tumor bearing mice after injection of Gd-DOTA-LAE (0.1 mmol/kg) and Gadovist (0.1 mmol/kg). b Contrast enhancement of normal tissue and tumor tissue. (contrast intensity post-injection/contrast intensity pre-injection × 100). c Contrast enhancement efficacy of Gd-DOTA-LAE and Gadovist in tumor tissue compared to normal tissue. [%, (Tumor post-injection/Tumor pre-injection) × 100 - (normal tissue post-injection/normal tissue pre-injection) × 100]